CTS Corporation Earnings Call Highlights Diversified Growth

CTS Corporation ((CTS)) has held its Q4 earnings call. Read on for the main highlights of the call.

CTS Corporation’s latest earnings call struck a cautiously upbeat tone, with management highlighting solid progress on diversification, margin expansion, and cash generation. Strength in medical, industrial, and aerospace & defense helped offset transportation headwinds and some defense-booking volatility, while guidance for 2026 pointed to steady, if modest, growth amid ongoing macro and supply-chain risks.

Revenue Growth Shows Steady, Not Spectacular, Momentum

CTS reported Q4 sales of $137 million, up 9% year over year, underscoring resilient demand despite softer transportation volumes and some program timing issues. Full-year 2025 revenue reached $541 million, a 5% increase from $515 million in 2024, signaling measured top-line growth in a choppy macro environment.

Diversification Strategy Paying Off in Higher-Margin Mix

Diversified end markets continued to gain ground, growing 16% year over year in Q4 and representing 59% of company revenue for the quarter and 57% for the full year. This shift away from more cyclical transportation exposure is supporting a richer margin profile and a more balanced portfolio across multiple industries.

Medical Segment Delivers Standout Performance

The medical business was a clear highlight, with Q4 sales soaring 41% year over year and full-year revenue climbing to $85 million from $70 million in 2024. Strong bookings, up 37% in the quarter and a book-to-bill of about 1.07 for 2025, suggest that medical momentum is likely to remain a key growth and margin driver.

Industrial Markets Show Recovery and Demand Strength

Industrial sales grew 16% year over year in Q4, while full-year revenue rose to £140 million from £125 million in 2024, signaling a broad-based recovery. Bookings jumped 22% in the quarter and full-year book-to-bill reached 1.11, pointing to a healthy pipeline and sustained demand in factory and automation-related applications.

Aerospace & Defense Growth Backed by Strategic Wins

Aerospace & defense posted full-year sales of $83 million, up 20% year over year, as CTS continued to win business in naval sonar, hydrophones, and RF filters. The addition of new customers and program awards is expanding the future backlog, reinforcing this segment as a key contributor to long-term growth.

Margins and Profitability Continue to Trend Higher

Profitability advanced, with Q4 adjusted gross margin at 39.1% and full-year adjusted gross margin at 38.5%, about 150 basis points higher. Adjusted EBITDA margin improved to 22.8%, up 40 basis points from 2024, reflecting operational efficiencies and a growing mix of higher-value diversified business.

Earnings Growth Underscores Operational Leverage

Earnings benefited from both volume and mix, as Q4 adjusted diluted EPS rose to $0.62 from $0.50 a year earlier and GAAP diluted EPS increased to $0.67 from $0.38. For the full year, adjusted diluted EPS improved to $2.23 versus $2.12 in 2024, even as the company navigated sector-specific headwinds and tax changes.

Robust Cash Generation Fuels Shareholder Returns

CTS generated strong cash flow, with $29 million of operating cash in Q4 and $102 million for the year, leaving it with $82 million in cash and $58 million of borrowings. The company returned $62 million to shareholders, including repurchases of about 1.4 million shares for roughly $57 million, and still has $90 million remaining under its authorization.

Bookings and Backlog Point to Sustained Demand

Company-level book-to-bill came in at 1.03 for Q4 and 1.04 for the full year, indicating orders continue to outpace shipments. Total booked business stood at roughly $1 billion at quarter end, providing solid visibility into future revenue even as individual end markets move at different speeds.

Transportation Segment Pressured by China and Commercial Vehicles

Transportation remained the primary drag, with full-year sales of $234 million, down 7% from $250 million in 2024 amid weak China conditions and soft commercial vehicle demand. Q4 transportation revenue was essentially flat year over year, highlighting ongoing challenges and limited near-term growth in this historically important segment.

SideQuest and Defense Bookings Impacted by Timing

SideQuest contributed $22 million for the year and $6 million in Q4, falling short of expectations due to slower government award and funding timing, though management expects a recovery in 2026. Defense bookings were down in Q4 despite being up 15% for the year, underscoring timing volatility rather than underlying demand weakness for longer-cycle programs.

Sequential Softness Highlights Demand Variability

While year-over-year figures were mostly positive, Q4 sales declined 4% sequentially from the prior quarter. Management framed this as normal demand variability across markets and timing of programs, but it underscores that growth is not on a straight-line trajectory, especially with transportation still under pressure.

Macro, Supply Chain, and Technology Adoption Risks

Management flagged tariff impacts, slower EV investment cycles, and commercial vehicle softness as risks that could cap transportation growth. They also cited potential pressure from rare earth and semiconductor supply, plus slower adoption of certain transportation technologies such as e-brake and footwell solutions, with some new wins, like a floor hinge, not contributing revenue until 2028.

Tax Changes Add a Modest Earnings Headwind

Regulatory developments also played a role, as changes in U.S. tax legislation trimmed about $0.03 from adjusted diluted EPS for 2025. While modest relative to overall earnings, this headwind underscores that policy and tax environments remain another variable for investors to monitor around the margin profile.

Guidance Signals Modest Growth and Ongoing Mix Shift

For 2026, CTS guided sales to $550 million–$580 million and adjusted diluted EPS of $2.30–$2.45, implying modest revenue growth and continued margin expansion. Management expects solid demand in medical, industrial, and aerospace & defense, aided by backlog and SideQuest normalization, while forecasting flat to slightly down transportation volumes and only gradual improvement in commercial vehicles later in the year.

CTS’s earnings call painted a picture of a company steadily transforming its portfolio and margin structure even as legacy transportation markets struggle. With diversified end markets gaining share, strong cash generation funding buybacks, and a cautious but positive 2026 outlook, the story for investors is one of measured growth, improving quality of earnings, and manageable macro and execution risks.